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ABSTRACT
Background. Mild cases of acute kidney injury (AKI) are identified by a small rise in serum creatinine (SCr) according to the
KDIGO AKI definition. The aim of this study was to examine the long-term outcomes of individuals with mild AKI.
Methods. This was a retrospective cohort study of all adult patients who underwent abdominal, cardiothoracic, vascular or
orthopaedic surgery at Landspitali–The National University Hospital of Iceland in 1998–2015. Incident chronic kidney
disease (CKD), progression of pre-existing CKD and long-term survival were compared between patients with mild Stage 1
AKI (defined as a rise in SCr of 26.5 lmol/L within 48 h post-operatively without reaching 1.5baseline SCr within 7 days),
and a propensity score-matched control group without AKI stratified by the presence of CKD.
Results. Pre- and post-operative SCr values were available for 47 333 (42%) surgeries. Of those, 1161 (2.4%) had mild Stage 1
AKI and 2355 (5%) more severe forms of AKI. Mild Stage 1 AKI was associated with both incident CKD and progression of
pre-existing CKD (P<0.001). After exclusion of post-operative deaths within 30 days, mild Stage 1 AKI was not associated
with worse 1-year survival in patients with preserved kidney function (94% versus 94%, P¼0.660), and same was true for
patients with pre-operative CKD (83% versus 82%, P¼0.870) compared with their matched individuals.
Conclusions. Mild Stage 1 AKI is associated with development and progression of CKD, but not with inferior 1-year survival.
These findings support the inclusion of a small absolute increase in SCr in the definition of AKI.
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INTRODUCTION
Acute kidney injury (AKI) is a common complication of surgery
[1] that has been associated with the development and/or pro-
gression of chronic kidney disease (CKD) and increased mortal-
ity [2–6].
In addition to a relative increase in serum creatinine (SCr) to
at least 1.5baseline within 7 days [7], an absolute rise in SCr of
26.5 lmol/L within 48 h without reaching 1.5baseline SCr
within 7 days is sufficient to make the diagnosis of AKI accord-
ing to current definitions [8, 9]. This is justified by several retro-
spective studies demonstrating an association between such a
small increase in SCr and short-term mortality [10, 11]. The use
of absolute changes in SCr to define AKI is, however, potentially
limited given the variability of baseline SCr, particularly among
those with underlying CKD [12]. Therefore, it is possible that the
subgroup of patients who fulfil the criteria for the diagnosis of
AKI solely by the small increase in SCr of 26.5 lmol/L differs
from other patients with AKI.
Few studies have focused on long-term outcomes after small
acute increases in SCr [11, 13–15]. Considering the sensitivity of
a small change in SCr measurements, there is a substantial risk
of both under- and over-diagnosing mild AKI depending on the
timing of the baseline value. Nevertheless, studies have shown
that adverse outcomes associate with even very small absolute
or relative in-hospital increases in SCr, although these studies
have primarily focused on mortality and the development of
end-stage kidney disease (ESKD) [12–14]. Further studies are
needed to examine whether the small absolute increase in SCr,
as included in current definitions, associates with long-term
survival and development of CKD or progression of pre-existing
CKD.
The aim of this study was to examine if post-operative mild
Stage 1 AKI, defined as the increase in SCr of 26.5 lmol/L
within 48 h, without reaching 1.5baseline SCr within 7 days, is
associated with long-term development of CKD, the progression
of pre-existing CKD and survival.
MATERIALS AND METHODS
Ethical approval
Approval for the study was obtained from the National
Bioethics Committee (14-139-V1) and the Data Protection
Authority in Iceland.
Study design and patient sample
This was a retrospective cohort study of all patients aged
18 years who underwent abdominal, cardiothoracic, vascular
or orthopaedic surgery at Landspitali–The National University
Hospital of Iceland from 1 January 1998 to 31 December 2015.
The study followed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guidelines for
observational studies [16]. All patients with pre-operative CKD
Stage 5 and repeated AKI episodes during surgical admissions
were excluded. Patients who died in hospital within 30 days of
surgery were excluded from the analysis of long-term outcomes
to eliminate the effects of short-term mortality on long-term
survival. Analysis that includes early deaths is presented in the
Supplementary Material. Patients who died in the first 90 days
after surgery and could therefore not be assessed for develop-
ment or progression of CKD were excluded from the analysis of
kidney-specific outcomes.
Data acquisition
Clinical data were extracted from electronic medical records.
Surgical codes, based on the Nordic Medico-Statistical
Committee Classification of Surgical Procedures (NCSP-IS, ver-
sion 1.14, www.nowbase.org), were used to classify the proce-
dures. International Classification of Diseases, Tenth revision
diagnosis codes were obtained from hospital records to assess
pre-operative comorbidity and were used to calculate the van
Walraven modification of the Elixhauser Comorbidity Index
score [17, 18]. All available pre- and post-operative SCr measure-
ments were collected from a nationwide database containing all
SCr measurements performed at the University Hospital in
1998–2007 and all SCr values in Iceland in 2008–16. These values
were used to define baseline SCr, determine pre-operative CKD
stage, assess post-operative AKI, and evaluate incident and pro-
gressive CKD following AKI. Date of death was obtained from
Statistics Iceland, censored on 20 May 2016.
Definitions
Baseline SCr was defined as the value closest to the surgery, out
of measurements available within 30 days before surgery. All
patients with available baseline and post-operative SCr were
evaluated for the presence of post-operative AKI according to
the SCr component of the KDIGO criteria [9]. Mild Stage 1 AKI
was defined as an increase in SCr of 26.5 lmol/L above base-
line within 48 h, without reaching a relative increase in SCr of
1.5baseline within 7 days.
The Chronic Kidney Disease Epidemiology Collaboration
equation was used to estimate glomerular filtration rate
(eGFR) [19]. CKD Stage 3 and above was defined as eGFR
<60 mL/min/1.73 m2, sustained for >90 days and CKD was
staged according to the GFR criteria of the KDIGO classification
system into Stages 3a, 3b, 4 and 5 [20].
Outcomes
The main outcomes of this study were development of incident
CKD, progression of pre-existing CKD and 1-year survival.
Incident CKD was defined as any patient who reached Stage 3
CKD and above by a decline in eGFR sustained for >90 days in
patients with a pre-operative eGFR60 mL/min/1.73 m2.
Progression of pre-existing CKD was defined as an increase of at
least one CKD stage, sustained for >90 days, in patients with
pre-operative CKD Stages 3 and 4.
Statistical analysis and data configuration
All statistical analysis was done in RStudio version 1.0.136 (R
Foundation for Statistical Computing, Vienna, Austria). A P
< 0.05 was considered statistically significant, and 95% confi-
dence intervals (CIs) are reported where appropriate. Data from
different datasets were combined and analysed based on indi-
viduals’ national personal identification number and date of
surgery.
The cohort was divided into groups of patients with no AKI,
mild Stage 1 AKI and more severe forms of AKI. For outcome
analysis, the cohort was further stratified into subgroups with
and without preoperative CKD Stage 3 and above. Change in in-
cidence over time was analysed with Poisson regression.
Comparison of baseline characteristics, comorbid conditions
and peri-operative factors between groups was carried out using
the Chi-square test, the t-test, Wilcoxon rank sum test, Kruskal–
Wallis test or analysis of variance as appropriate.
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Progression of CKD and survival among patients with mild
Stage 1 AKI was compared with a propensity score-matched
control group without AKI (1:1) (Supplementary Material). This
comparison was performed separately for groups with and
without pre-operative CKD Stage 3 and above. The propensity
score in the survival analysis was based on: age and sex; base-
line eGFR; previous history of hypertension, diabetes mellitus,
ischaemic heart disease, congestive heart failure, chronic ob-
structive pulmonary disease (COPD), liver disease and malig-
nancy; year and type of surgery; and diagnosis of myocardial
infarction or sepsis during the hospitalization. The propensity
score in analysis of incident or progressive CKD included
matching on age, sex, baseline eGFR, previous diagnosis of hy-
pertension, diabetes, ischaemic heart disease or congestive
heart failure, and year and type of surgery. The Elixhauser
Comorbidity Index did not improve matching and was therefore
not included in the final models. Matching was evaluated by
comparing standardized differences of the matched variables
with a standardized mean difference <0.1 considered adequate
(Supplementary data, Tables SI–SIV) [21]. One-year survival and
5-year development of incident CKD or progression of pre-exist-
ing CKD were plotted as Kaplan–Meier curves and groups were
compared with a stratified log-rank test. To examine the consis-
tency of the results, a subgroup analysis based on the type of
surgery was also performed (Supplementary data, Table SV).
RESULTS
A total of 64 535 patients underwent 116 358 abdominal, cardio-
thoracic, vascular or orthopaedic surgical operations during the
study period. Baseline and post-operative SCr measurements
for evaluation of AKI were available for 48 873 (42%) surgical pro-
cedures. A total of 1540 procedures were excluded due to the
presence of pre-operative Stage 5 CKD (Figure 1). Thus, 47 333
surgical procedures were included in the analysis. In the follow-
ing analysis, the incidence is reported per surgical procedure for
the subset of patients with available pre- and post-operative
SCr measurements.
Incidence
AKI occurred following 3516 (7.4%) surgical procedures, of which
1161 (2.4%) were classified as mild Stage 1 AKI and 2355 (5.0%)
as more severe forms of AKI. The mean annual incidence of AKI
was 74.2/1000 surgeries/year. The incidence of mild Stage 1 AKI
decreased throughout the study period (3% per year, 95% con-
fidence interval [CI] 2% to 5%, P< 0.001). There were 561
cases of recurrent AKI episodes that were excluded from the
remaining analyses (Figure 1).
Patient characteristics
Patients with mild Stage 1 AKI were older (75 versus 68 years,
P< 0.001), more likely to be male (66% versus 54%, P< 0.001),
and had longer median (interquartile range [IQR]) length of stay
(10 versus 6 days, P< 0.001) and a higher comorbidity burden
compared with patients without AKI (Table 1). The comorbid-
ities included CKD (56% versus 22%, P< 0.001), diabetes (14%
versus 6%, P< 0.001), ischaemic heart disease (50% versus 29%,
P< 0.001) and congestive heart failure (24% versus 9%, P< 0.001).
When compared with patients with more severe forms of AKI,
those with mild Stage 1 AKI were more likely to have CKD (56%
versus 38%, P< 0.001), diabetes (14% versus 11%, P< 0.001),
ischaemic heart disease (50% versus 42%, P< 0.001) and
congestive heart failure (24% versus 17%, P< 0.001) (Table 1).
Patients with mild Stage 1 AKI had significantly shorter
median length of hospital stay than those with more severe
AKI, 10 (5–19) versus 12 (6–24) days (P< 0.001).
Overall, 11 236 (24%) patients with baseline and post-
operative SCr measurements available had pre-existing CKD
Stage 3 or 4 prior to surgery. Of these, 1550 (14%) developed
post-operative AKI compared with 2009 (5%) patients without
CKD (P< 0.001). The frequency of mild Stage 1 AKI was 1, 4, 7
and 10% in patients with no CKD and CKD Stages 3a, 3b and 4,
respectively (P< 0.001).
Development of incident CKD Stages 3–5 or progression
of pre-existing CKD
The median (IQR) follow-up time for the assessment of long-
term kidney function was 3.7 (1.4–7.3) years. There were 2350
(5%) patients without AKI, 134 (14%) with mild Stage 1 AKI and
516 (26%) patients with more severe AKI who died in the first
90 days after surgery and could therefore not be assessed for de-
velopment or progression of CKD (P< 0.001). After 5 years of
follow-up among patients without pre-operative CKD, incident
CKD Stages 3–5 occurred in 6888 (26%), 198 (57%) and 497 (60%)
patients without AKI, with mild Stage 1 AKI and with more se-
vere AKI, respectively (P< 0.001). Progression of pre-existing
CKD within 5 years of surgery occurred in 3755 (57%), 260 (74%)
and 310 (75%) patients without AKI, with mild Stage 1 AKI and
those with more severe AKI, respectively (P< 0.001). During
5 years following surgery, 43 (0.1%) patients who did not experi-
ence AKI, 4 (1%) with mild Stage 1 AKI and 4 (0.4%) patients with
more severe AKI required renal replacement therapy for ESKD
(P< 0.001).
For further analysis of mild Stage 1 AKI, each patient was
assigned a propensity score-matched control, stratified by pre-
existing CKD. Propensity score matching was complete for
all patients with mild Stage 1 AKI (100%) in all the analyses.
Matching properties are further demonstrated in
Supplementary data, Tables SI–SIV. Patients without pre-opera-
tive CKD who developed mild Stage 1 AKI were significantly
more likely to develop CKD Stages 3–5 in the ensuing 5 years
compared with propensity score-matched control patients
without AKI (57% versus 41%, P< 0.001; Figure 2A). Patients with
pre-existing CKD Stage 3 or 4 who developed mild Stage 1 AKI
were more likely to progress to a higher CKD stage than their
propensity score-matched controls without AKI (74% versus
63%, P< 0.001; Figure 2B). The results were similar when the
whole follow-up period was included in the analysis and when
surgical procedure subgroups were studied (Supplementary
data, Table SV).
Survival
For patients without pre-operative CKD (eGFR>60 mL/min/1.73 m2),
the 30-day survival was 98, 92 and 81% in patients without AKI,
in those with mild Stage 1 AKI and in patients with more severe
AKI, respectively (P< 0.001). The 30-day survival of patients
with pre-operative CKD was 95% in patients who did not de-
velop AKI, 88% in those with mild Stage 1 AKI and 75% in
patients with more severe AKI (P< 0.001).
The median (IQR) follow-up time for the assessment of sur-
vival was 5.3 (2.3–9.0) years. For the analysis of long-term sur-
vival, in-hospital deaths within 30 days were excluded
(Figure 1). The 1-year survival among patients without pre-oper-
ative CKD was 92, 87 and 71% in patients without AKI, with mild
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Stage 1 AKI and in patients with more severe AKI, respectively
(P< 0.001). For patients with pre-operative CKD, the 1-year sur-
vival was 80, 73 and 63% in patients without AKI, with mild
Stage 1 AKI and with more severe AKI, respectively (P< 0.001).
When patients with mild Stage 1 AKI were compared with
propensity score-matched controls, stratified by pre-existing
CKD, there was no difference in 1-year survival of individuals
without pre-operative CKD (94% versus 94%, P¼ 0.660;
Figure 3A). Furthermore, 1-year survival of patients with pre-op-
erative CKD Stage 3 and above and mild Stage 1 AKI was similar
to the control group without AKI (83% versus 82%, P¼ 0.870;
Figure 3B). The results were similar when the whole follow-up
period was included in the analysis and for each individual
surgical procedure subgroup (Supplementary data, Table SV).
Analyses including patients who died within 30 days of surgery
are demonstrated in Supplementary data, Figures S1 and S2.
DISCUSSION
In this study, one-third of all AKI cases were mild Stage 1 AKI.
Patients with mild Stage 1 AKI had a higher comorbidity burden
than both patients without AKI and those with more severe
AKI, most notably a very high rate of pre-existing CKD Stage 3
or 4. Mild Stage 1 AKI was associated with both incident CKD
and progression of pre-existing CKD during 5 years of follow-up
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FIGURE 1: Flowchart showing the total study cohort, exclusion of patients and stratification of AKI categories for analysis.
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Table 1. Comparison of baseline characteristics between groups of patients without AKI, with mild Stage 1 AKI and with more severe AKI
No AKI (n¼ 43 817) Mild Stage 1 AKI (n¼ 1161) More severe AKI (n¼2355) P-value
Age, years 68 (57–77) 75 (68–81)* 74 (65–81) <0.001
Sex, male 23 566 (54) 772 (66)* 1306 (55) <0.001
Baseline SCr, lmol/L 79 (66–96) 110 (88–148)* 87 (68–114) <0.001
No CKD 34 131 (78) 508 (44) 1458 (62) –
CKD
Stage 3a 5739 (13) 264 (23) 447 (19) –
Stage 3b 3043 (7) 267 (23) 314 (13) –
Stage 4 904 (2) 122 (10)* 136 (6) <0.001
Hypertension 7380 (17) 346 (30)* 616 (26) <0.001
Diabetes mellitus 2848 (6) 167 (14)* 259 (11) <0.001
Ischaemic heart disease 12 757 (29) 586 (50)* 982 (42) <0.001
Congestive heart failure 3956 (9) 276 (24)* 409 (17) <0.001
COPD 2717 (6) 92 (8)* 202 (9) <0.001
Liver disease 560 (1) 13 (1) 48 (2) 0.005
Neoplasm 11 221 (26) 353 (30)* 698 (30) <0.001
Preoperative morbidity assessment
Elixhauser Comorbidity Index >1 10 001 (23) 344 (30)* 680 (29) <0.001
Type of surgery
Abdominal
Major 5928 (14) 133 (11) 375 (16) –
Minor 4681 (11) 81 (7) 143 (6) –
Cardiothoracic –
Major 9674 (22) 392 (34) 700 (30) –
Minor 7649 (17) 224 (19) 424 (18) –
Vascular –
Major 782 (2) 42 (4) 72 (3) –
Minor 2337 (5) 44 (4) 85 (4) –
Orthopaedic –
Major 9706 (22) 204 (18) 454 (19) –
Minor 3060 (7) 41 (4)* 102 (4) <0.001
Length of stay (days) 6 (3–10) 10 (5–19)* 12 (6–24) <0.001
Data are presented as median (IQR) for continuous variables or number (percentage) for categorical variables. Data were compared between no AKI, mild Stage 1 AKI
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FIGURE 2: (A) Incident CKD within 5 years following surgery in patients without preoperative CKD who experienced mild Stage 1 AKI compared with a propensity
score-matched control group without AKI (P<0.001). (B) Progression of CKD within 5 years after surgery in patients with pre-operative CKD who developed mild Stage 1
AKI and compared with a propensity score-matched control group without AKI (P<0.001). Propensity score matched for: age, sex, year of surgery, type of surgery, base-
line eGFR, and previous diagnosis of hypertension, diabetes mellitus, ischaemic heart disease and congestive heart failure.






/ckj/article/14/1/237/5733044 by Landspitalinn user on 09 June 2021
with mild Stage 1 AKI had increased 30-day mortality compared
with those without AKI, but when these early deaths were ex-
cluded, the 1-year survival was similar to controls, regardless of
pre-operative kidney function.
Numerous studies have demonstrated an association be-
tween severe AKI and the development or progression of pre-
existing CKD [22, 23]. However, there are limited data available
on the association of small rises in SCr with long-term develop-
ment or progression of CKD. A study of Medicaid beneficiaries
with myocardial infarction showed an association of small ab-
solute in-hospital SCr increase with both development of kid-
ney failure requiring renal replacement therapy and death [14].
Increase in SCr of >9 lmol/L was associated with both out-
comes, but the study did not assess more subtle kidney-specific
outcomes such as incident or progressive CKD. In another study
of >29 000 veterans undergoing cardiac surgery, Ishani et al. [13]
showed an increase in SCr of 1.01–1.24baseline over the first
seven post-operative days to associate with both incident CKD
and progression of pre-existing CKD. The results of these two
studies are in line with our findings despite differences in the
cohorts and the definitions of mild AKI used. Indeed, neither of
the aforementioned studies conforms with the current AKI defi-
nitions, although several of the patients are likely to have had
an absolute increase of 26.5 lmol/L above baseline SCr.
Few studies have focused on long-term survival following a
small increase in SCr in the hospital or post-operative setting.
A large retrospective study of patients with acute myocardial
infarction who survived to hospital discharge showed that
increase in SCr of only 9 lmol/L during hospitalization, when
compared with stable or reduced SCr, was associated with
worse long-term mortality (median follow-up 4.1 years).
However, the baseline SCr was determined on the day of admis-
sion, which may have resulted in an overestimation of the base-
line SCr [14]. In contrast, another study that included >4300
patients undergoing cardiac or thoracic aortic surgery found
that small post-operative increase in SCr of 0–44 lmol/L within
48 h following surgery, compared with a decrease in SCr of 9 to
26.5 lmol/L, was associated with a nearly 3-fold increase in 30-
day mortality, but was not associated with long-term mortality
[11]. These results are similar to our findings. A recent study of
>76 000 patients with myocardial infarction carried out in the
USA showed that mild AKI, defined as a rise in SCr of 26.5–
44 lmol/L during admission, regardless of the baseline SCr, was
associated with increased 1-year mortality after excluding in-
hospital mortality [15]. This finding differs from our results,
possibly because of discrepancies in the definition of mild AKI,
as baseline SCr, which was not considered in the American
study, would be expected to substantially affect the classifica-
tion of AKI [24]. In parallel with our study, the majority of
patients who developed mild AKI had pre-operative CKD, but in
general, the prevalence of CKD in the US study was higher than
in our cohort.
The mechanism behind the observed association between
mild Stage 1 AKI and the development and progression of CKD
is unclear. Results of animal studies suggest several pathobio-
logical pathways leading to kidney disease progression, such as
maladaptive repair and dysfunctional regeneration [25, 26]. It
has been proposed that the failure of regenerating tubules to
differentiate following an AKI episode drives tubulointerstitial
inflammation and fibrosis [26]. Furthermore, endothelial injury
may induce a vicious cycle of tissue hypoxia that perpetuates
cellular injury, dampens repair and causes progressive tissue
damage [26]. While a full recovery would generally be expected
following an episode of mild AKI, it cannot be ruled out that
even mild episodes could lead to tissue hypoxia and damage
resulting in the development and progression of CKD. On the
other hand, the high comorbidity burden observed in patients
with mild Stage 1 AKI might suggest that mild AKI does not re-
flect a true kidney injury, but rather reduced renal physiological
reserve uncovered by the stress of the surgery and the associ-
ated haemodynamic instability and inflammatory response
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FIGURE 3: (A) One-year survival of patients without pre-operative CKD who developed mild Stage 1 AKI compared with a propensity score-matched control group with-
out AKI. Individuals who died within 30 days after surgery were excluded. One-year survival was 94% in both the mild Stage 1 AKI group and in the propensity score-
matched control group (P¼0.660). (B) One-year survival of patients with preoperative CKD who developed mild Stage 1 AKI compared with a propensity score-matched
control group without AKI. Individuals who died within 30 days of surgery were excluded. One-year survival was 83% in the mild Stage 1 AKI group and 82% in the pro-
pensity score-matched control group (P¼ 0.870). Propensity score matched for: age, sex, year of surgery, type of surgery, baseline eGFR, diagnosis of myocardial infarc-
tion or sepsis during hospitalization and previous history of hypertension, diabetes mellitus, ischaemic heart disease, congestive heart failure, COPD, liver disease and
malignancy.
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prone to subsequent development of incident CKD or progres-
sion of pre-existing CKD.
The main strength of our study is the extensive nationwide
SCr database that allows accurate detection and thorough long-
term evaluation of incident CKD and progression of pre-existing
CKD. Furthermore, the data on mortality are complete for all
patients residing in Iceland. Nevertheless, the study has certain
limitations including the retrospective observational design
that we have attempted to mitigate by comparing the outcomes
with propensity score-matched control groups. Unfortunately,
information on the aetiology of AKI in our cohort is lacking, but
the occurrence in the peri-operative period makes haemody-
namic alterations leading to ischaemia and tubular injury a
likely pathophysiological mechanism. Daily measurements of
SCr were not available for all patients and, therefore, it is possi-
ble that some AKI episodes were missed or misclassified.
Finally, baseline or post-operative SCr was missing in 58% of
our surgical cohort. However, patients without pre- and/or post-
operative SCr measurements were generally healthier and
underwent less extensive surgical procedures and, thus, would
be considered less likely to develop post-operative AKI.
In conclusion, our study showed that mild Stage 1 AKI
accounts for one-third of all post-operative AKI episodes and is
associated with incident CKD, progression of pre-existing CKD
and early mortality, but not with 1-year survival. We believe
that these findings support the inclusion of a small absolute
increase in SCr in the definition of AKI. Finally, our results em-
phasize the importance of meticulous follow-up of patients
who experience mild Stage 1 AKI.
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